Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vickie Bowcut

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein InteractionJohn M Ketcham, Jacob Haling, Shilpi Khare, et al.
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.
Nature Medicine|October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitorJill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Molecular Cancer Therapeutics|June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide LoadingNiranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery|August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted CancerLars D Engstrom, Ruth Aranda, Laura Waters, et al.
Cancer Discovery|October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsJill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein InteractionJohn M Ketcham, Jacob Haling, Shilpi Khare, et al.
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.
Nature Medicine|October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitorJill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Molecular Cancer Therapeutics|June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide LoadingNiranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery|August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted CancerLars D Engstrom, Ruth Aranda, Laura Waters, et al.
Cancer Discovery|October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsJill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Pageof 1